Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Estimates By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST) announced its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), FiscalAI reports. The firm had revenue of $7.56 million during the quarter, compared to analysts’ expectations of $11.02 million.

Aquestive Therapeutics Stock Up 2.9%

Shares of AQST opened at $3.88 on Wednesday. The stock has a market capitalization of $486.98 million, a P/E ratio of -5.97 and a beta of 1.49. The firm has a fifty day simple moving average of $4.62 and a two-hundred day simple moving average of $4.20. Aquestive Therapeutics has a twelve month low of $2.93 and a twelve month high of $6.85.

Wall Street Analyst Weigh In

AQST has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, October 16th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Aquestive Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.60.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, CEO Daniel Barber sold 25,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $4.22, for a total value of $105,500.00. Following the transaction, the chief executive officer owned 627,317 shares in the company, valued at approximately $2,647,277.74. The trade was a 3.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the transaction, the insider directly owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. This trade represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 58,750 shares of company stock worth $271,675 in the last 90 days. Corporate insiders own 6.81% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.